Logo image of ALQGC.PA

QUANTUM GENOMICS SAS-REGR (ALQGC.PA) Stock Fundamental Analysis

EPA:ALQGC - Euronext Paris - Matif - FR0011648971 - Common Stock - Currency: EUR

0.0721  0 (-1.77%)

Fundamental Rating

1

ALQGC gets a fundamental rating of 1 out of 10. The analysis compared the fundamentals against 72 industry peers in the Biotechnology industry. ALQGC may be in some trouble as it scores bad on both profitability and health. ALQGC is valued correctly, but it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

0

1. Profitability

1.1 Basic Checks

In the past year ALQGC has reported negative net income.
ALQGC had negative earnings in each of the past 5 years.
In the past 5 years ALQGC always reported negative operating cash flow.
ALQGC.PA Yearly Net Income VS EBIT VS OCF VS FCFALQGC.PA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 -10M -20M -30M

1.2 Ratios

ALQGC's Return On Assets of -84.63% is on the low side compared to the rest of the industry. ALQGC is outperformed by 80.00% of its industry peers.
With a Return On Equity value of -726.18%, ALQGC is not doing good in the industry: 75.71% of the companies in the same industry are doing better.
Industry RankSector Rank
ROA -84.63%
ROE -726.18%
ROIC N/A
ROA(3y)-87.78%
ROA(5y)-71.29%
ROE(3y)-517.57%
ROE(5y)-335.54%
ROIC(3y)N/A
ROIC(5y)N/A
ALQGC.PA Yearly ROA, ROE, ROICALQGC.PA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2015 2016 2017 2018 2019 2020 2021 2022 2023 -200 -400 -600

1.3 Margins

ALQGC does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ALQGC.PA Yearly Profit, Operating, Gross MarginsALQGC.PA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2015 2016 2017 2018 2019 2020 2021 2022 2023 -20K -40K -60K

More info and screens

3

2. Health

2.1 Basic Checks

ALQGC does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, ALQGC has about the same amount of shares outstanding.
The number of shares outstanding for ALQGC has been increased compared to 5 years ago.
Compared to 1 year ago, ALQGC has a worse debt to assets ratio.
ALQGC.PA Yearly Shares OutstandingALQGC.PA Yearly Shares OutstandingYearly Shares Outstanding 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M
ALQGC.PA Yearly Total Debt VS Total AssetsALQGC.PA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

2.2 Solvency

Based on the Altman-Z score of -11.61, we must say that ALQGC is in the distress zone and has some risk of bankruptcy.
ALQGC has a worse Altman-Z score (-11.61) than 84.29% of its industry peers.
A Debt/Equity ratio of 4.49 is on the high side and indicates that ALQGC has dependencies on debt financing.
Looking at the Debt to Equity ratio, with a value of 4.49, ALQGC is doing worse than 72.86% of the companies in the same industry.
Industry RankSector Rank
Debt/Equity 4.49
Debt/FCF N/A
Altman-Z -11.61
ROIC/WACCN/A
WACC7.48%
ALQGC.PA Yearly LT Debt VS Equity VS FCFALQGC.PA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2015 2016 2017 2018 2019 2020 2021 2022 2023 0 10M -10M 20M

2.3 Liquidity

A Current Ratio of 2.73 indicates that ALQGC has no problem at all paying its short term obligations.
With a Current ratio value of 2.73, ALQGC perfoms like the industry average, outperforming 60.00% of the companies in the same industry.
ALQGC has a Quick Ratio of 2.73. This indicates that ALQGC is financially healthy and has no problem in meeting its short term obligations.
ALQGC has a Quick ratio (2.73) which is comparable to the rest of the industry.
Industry RankSector Rank
Current Ratio 2.73
Quick Ratio 2.73
ALQGC.PA Yearly Current Assets VS Current LiabilitesALQGC.PA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2015 2016 2017 2018 2019 2020 2021 2022 2023 10M 20M 30M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an impressive 87.28% over the past year.
ALQGC shows a very negative growth in Revenue. In the last year, the Revenue has decreased by -98.34%.
Measured over the past years, ALQGC shows a very negative growth in Revenue. The Revenue has been decreasing by -79.70% on average per year.
EPS 1Y (TTM)87.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.58%
Revenue 1Y (TTM)-98.34%
Revenue growth 3Y-79.7%
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y6121.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue Next Year1744.53%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No EPS estimates are available, so we could not analyze the future EPS growth and evolution.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ALQGC.PA Yearly Revenue VS EstimatesALQGC.PA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2014 2015 2018 2019 2020 2021 2022 2023 2024 20M 40M 60M 80M 100M
ALQGC.PA Yearly EPS VS EstimatesALQGC.PA Yearly EPS VS EstimatesYearly EPS VS Estimates 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 0 1 2 3 4

More info and screens

4

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ALQGC. In the last year negative earnings were reported.
A Price/Forward Earnings ratio of 0.02 indicates a rather cheap valuation of ALQGC.
Based on the Price/Forward Earnings ratio, ALQGC is valued cheaper than 100.00% of the companies in the same industry.
ALQGC is valuated cheaply when we compare the Price/Forward Earnings ratio to 36.80, which is the current average of the S&P500 Index.
Industry RankSector Rank
PE N/A
Fwd PE 0.02
ALQGC.PA Price Earnings VS Forward Price EarningsALQGC.PA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ALQGC.PA Per share dataALQGC.PA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 2 3 4

4.3 Compensation for Growth

The low PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates a rather cheap valuation of the company.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2YN/A
EPS Next 3YN/A

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ALQGC!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

QUANTUM GENOMICS SAS-REGR

EPA:ALQGC (10/24/2024, 7:00:00 PM)

0.0721

0 (-1.77%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)10-22 2024-10-22
Earnings (Next)N/A N/A
Inst OwnersN/A
Inst Owner ChangeN/A
Ins OwnersN/A
Ins Owner ChangeN/A
Market Cap5.00M
Analysts34.29
Price Target10.2 (14047.02%)
Short Float %N/A
Short RatioN/A
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)0%
PT rev (3m)0%
EPS NQ rev (1m)N/A
EPS NQ rev (3m)N/A
EPS NY rev (1m)0%
EPS NY rev (3m)0%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE 0.02
P/S 496.96
P/FCF N/A
P/OCF N/A
P/B 11.45
P/tB 11.45
EV/EBITDA N/A
EPS(TTM)-0.09
EYN/A
EPS(NY)4.34
Fwd EY6021.43%
FCF(TTM)N/A
FCFYN/A
OCF(TTM)N/A
OCFYN/A
SpS0
BVpS0.01
TBVpS0.01
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -84.63%
ROE -726.18%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-87.78%
ROA(5y)-71.29%
ROE(3y)-517.57%
ROE(5y)-335.54%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-ScoreN/A
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 4.49
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 2.73
Quick Ratio 2.73
Altman-Z -11.61
F-ScoreN/A
WACC7.48%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)87.28%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%92.58%
EPS Next Y6121.43%
EPS Next 2YN/A
EPS Next 3YN/A
EPS Next 5YN/A
Revenue 1Y (TTM)-98.34%
Revenue growth 3Y-79.7%
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next Year1744.53%
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y89.57%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year3919.47%
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1YN/A
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1YN/A
OCF growth 3YN/A
OCF growth 5YN/A